Headquartered in Florham Park, NJ Fiscal year ends December NASDAQ: PHAT phathompharma.com
Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. The company has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada. Phathom markets vonoprazan in the United States under the VOQUEZNA brand for multiple GI indications including Non-Erosive GERD in adults, healing and maintenance of healing of Erosive GERD in adults, and as part of combination therapy (VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK) for the treatment of H. pylori infection in adults. The company's commercial strategy is focused on gastroenterology specialists, and it is pursuing pipeline expansion including as-needed dosing for Non-Erosive GERD and evaluation in Eosinophilic Esophagitis (EoE). Phathom trades on Nasdaq under the ticker PHAT. Updated
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (NASDAQ:PHAT) to Overweight from Equal Weight on Friday, raising her price target to $18 from $16. With the stock trading at $10.69 — down nearly…
Joel South Phathom Pharmaceuticals is a biopharmaceutical company focused on the commercialization and development of novel treatments for gastrointestinal diseases. The company has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada.
The Wall Street consensus 12-month price target for PHAT is $20.45.
